{"filing":{"accession_number":"0001437749-26-019660","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"mbrx20260604_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/mbrx20260604_8k.htm"},"events":[{"id":3671,"run_id":3220,"accession_number":"0001437749-26-019660","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The disclosure announces results from an independent market landscape assessment for Annamycin in R/R AML, a clinical-stage asset. While this is material information about a key product candidate's competitive positioning, it does not fit cleanly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined events). The assessment results could influence investor perception of the drug's commercial viability, warranting classification as other_material.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-05","items":[{"id":4670,"accession_number":"0001437749-26-019660","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure announces results from an independent market landscape assessment for Annamycin in R/R AML, a clinical-stage asset. While this is material information about a key product candidate's competitive positioning, it does not fit cleanly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined events). The assessment results could influence investor perception of the drug's commercial viability, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:50:24.708157+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4670,"accession_number":"0001437749-26-019660","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure announces results from an independent market landscape assessment for Annamycin in R/R AML, a clinical-stage asset. While this is material information about a key product candidate's competitive positioning, it does not fit cleanly into the standard taxonomy categories (not earnings, M\u0026A, litigation, impairment, or other defined events). The assessment results could influence investor perception of the drug's commercial viability, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T16:50:24.708157+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-06-05"}]}